In our series of 34 patients with prolactinomas, which is, to the best of our knowledge, the largest prolactinoma series for SST and D2R receptor immunohistochemical staining, 22 (64.7%) were DA-resistant and 4 (11.8%) intolerant to DA therapy. Here, SST is linked to prolactin-producing pituitary gland adenoma.